Research programme: bradykinin B1 receptor antagonists - Amgen
Latest Information Update: 04 Nov 2017
At a glance
- Originator Amgen
- Class Amides; Naphthalenes; Piperazines; Pyrazines; Small molecules; Sulfonamides; Sulfones
- Mechanism of Action Bradykinin B1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA
- 01 Sep 2011 Preclinical development is ongoing in USA